Loading...

GLUE MONTE ROSA THERAPEUTICS INC Disposals and divestitures 8-K Filing

MNT

GL

MONTE ROSA THERAPEUTICS INC

(GLUE)

2025 8-K

Management Change

Stock Offering Details

Stock Agreement Termination

Positive Data Announcement

Positive Study Results

Financial Results Update

Collaboration Agreement

Financial Statements

Financial Statements

Financial Results

Financial Update

Director Appointment

Clinical Trial Update

License Agreement

Financial Results Announcement

Annual Meeting of Stockholders

Promotion of Jennifer Champoux

Underwriting Agreement for ...

Earnings Reports

Resignation of Chief Scient...

Financial Results and Corpo...

Corporate Update and Key Mi...

Financial Results Announcement

Securities Purchase Agreement

Collaboration and License A...

Financial Results Announcement

Appointment of Director

Amendment Approval at Annua...

Financial Results Announcement

Appointment of Director

Financial Results and Corpo...

Corporate Update and Antici...

External Links:

On December 16, 2025, Monte Rosa Therapeutics reported positive interim results from their Phase 1/2 study of MRT-2359 in combination with enzalutamide for prostate cancer patients, showing a 100% disease control rate in patients with AR mutations and initiating further trials planned for 2026.

AI Assistant

MONTE ROSA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.